Ocuphire Pharma Investor Day Presentation Deck
Large Global/US Market Opportunity in Retinal Disease
DME Retinal US Markets Served by Anti-VEGF Injections Alone are Greater than $10B+ Today
DR
37
Global Disease Prevalence (Patients)
113 M
WAMD, RVO,
DME
combined
5 M
GA
93 M
DR
$13 B
US Revenues
1 M
Dry
AMD
↑ Aging
↑ Access
↑ Diabetes
↑ New Rx Products
Global Forecasted Disease Prevalence (5-10 years)
130 M
WAMD, RVO,
DME* combined
Anti-VEGF Injectable US Revenue
4%
CAGR
10 M
GA
110 M
DR*
*As early intervention options and exams are performed, there may be less DME and more DR
$20 B
US Projected Revenue
2 M
Dry
AMD
Market Scope 2020
J Glob Health. 2019 Jun; 9(1): 010427
Tilahun M et. al, Prevalence of Diabetic Retinopathy and Its Associated Factors among Diabetic Patients at Debre Markos Referral Hospital, Northwest Ethiopia, 2019: Hospital-Based Cross-Sectional Study.
Diabetes Metab Syndr Obes. 2020;13:2179-2187
$5+B
GA Revenues
$10+B
Oral Rx Revenues
Ocuphire
PHARMAView entire presentation